The role of DLL1 in long-term vascular normalization and cancer immunotherapy
Guardado en:
Autores principales: | Qiaozhen Wu, Yuhui Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
China Anti-Cancer Association
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bfd4af26651b4c39991ab6c26d99c494 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cancer immunology and immunotherapy
por: Xiubao Ren
Publicado: (2021) -
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Amaia Lujambio, et al.
Publicado: (2021) -
Novel emerging biomarkers to immunotherapy in kidney cancer
por: Yasser Ged, et al.
Publicado: (2021) -
Immunotherapy in breast cancer: A clinician's perspective
por: Sibapriya Chaudhuri, et al.
Publicado: (2021) -
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)